{"cluster": 48, "subcluster": 17, "abstract_summ": "Health care professionals caring for patients with COVID-19 need to be aware that there is a positive association between MAFLD and severe illness with COVID-19.Importance: Multiple sclerosis patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, no study has identified clinical characteristics of multiple sclerosis associated with worse COVID-19 outcomes.While metabolic associated fatty liver disease (MAFLD) affects a quarter of world population, its impact on COVID-19 severity has not been characterized.While diabetes is known to aggravate COVID\u201019 severity, it is not known whether nondiabetic patients with metabolic dysfunction are also more prone to more severe disease.Univariate analysis was performed on liver phenotypic biomarkers to determine if these variables increased risk of symptomatic COVID-19, and compared to previously described risk factors associated with severe COVID-19, including to age, ethnicity, gender and obesity, Findings Increased liver fat was associated with a higher risk for symptomatic confirmed COVID-19 in this population in univariate analysis(OR:1.85, p=0.03).Conclusions and Relevance In this registry-based cohort study of patients with MS, age, EDSS, and obesity were independent risk factors for severe COVID-19; there was no association found between DMTs exposure and COVID-19 severity.", "title_summ": "Metabolic associated fatty liver disease is associated with severity of COVID-19.COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionHIGH LIVER FAT ASSOCIATES WITH HIGHER RISK OF DEVELOPING SYMPTOMATIC COVID-19 INFECTION - INITIAL UK BIOBANK OBSERVATIONSPreeclampsia\u2010like syndrome induced by severe COVID\u201019: a prospective observational studyDiabetes is a risk factor for the progression and prognosis of COVID\u201019COVID-19 and diabetes mellitus: A need for prudence in elderly patients from a pooled analysisMetabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patientsInfluence of diabetes mellitus on the severity and fatality of SARS\u2010CoV\u20102 infectionObesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver diseaseCorrelation between Heart fatty acid binding protein and severe COVID-19: A case-control studyMetabolic dysfunction associated fatty liver disease increases risk of severe Covid-19.Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.", "title_abstract_phrases": "Health care professionals caring for patients with COVID-19 need to be aware that there is a positive association between MAFLD and severe illness with COVID-19.COVID-19 in Multiple Sclerosis Patients and Risk Factors for Severe InfectionImportance: Multiple sclerosis patients have been considered a higher-risk population for COVID-19 due to the high prevalence of disability and disease-modifying therapy use; however, no study has identified clinical characteristics of multiple sclerosis associated with worse COVID-19 outcomes.Univariate analysis was performed on liver phenotypic biomarkers to determine if these variables increased risk of symptomatic COVID-19, and compared to previously described risk factors associated with severe COVID-19, including to age, ethnicity, gender and obesity, Findings Increased liver fat was associated with a higher risk for symptomatic confirmed COVID-19 in this population in univariate analysis(OR:1.85, p=0.03).While metabolic associated fatty liver disease (MAFLD) affects a quarter of world population, its impact on COVID-19 severity has not been characterized.While diabetes is known to aggravate COVID\u201019 severity, it is not known whether nondiabetic patients with metabolic dysfunction are also more prone to more severe disease.The identification of these risk factors should provide the rationale for an individual strategy regarding clinical management of patients with MS during the COVID-19 pandemic."}